Welcome Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. In advancing our first product, COMETRIQ, from discovery to market, we have established an effective and integrated infrastructure that encompasses the entire biopharmaceutical development continuum. We are committed to excellence in all aspects of our work and are dedicated to improving the care and outcome of cancer patients. Exelixis In The News Sep 1, 2014 Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer Jul 31, 2014 Exelixis Announces Second Quarter 2014 Financial Results Jul 16, 2014 Exelixis to Release Second Quarter 2014 Financial Results on Thursday, July 31, 2014 Jul 14, 2014 Exelixis Announces Positive Top-Line Results for Phase 3 Pivotal Trial of Cobimetinib in Combination With Vemurafenib in Patients With BRAF V600 Mutation-Positive Advanced Melanoma More News View Important Safety Information including Boxed Warning Stock NASDAQ: EXEL Sep 5 2014 4:00pm EDT PRICE: 1.85 0 VOLUME: 5,458,962 SHARES 20 minute delay About Us COMETRIQ® Pipeline Clinical Trials Medical Information Investors & Media Responsibility Careers © Exelixis, Inc. 2014 Website design: Hane Chow, Inc. Privacy Terms of Use

About Us At Exelixis, our vision is to be a commercial world-class biotechnology company. Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. In advancing COMETRIQ® (cabozantinib), our first commercial product, from discovery to market, we have put in place an effective and integrated infrastructure that encompasses the entire biopharmaceutical development continuum. Areas of expertise include early discovery and preclinical development, clinical development, translational medicine, regulatory affairs, and sales and marketing, among other functions. In addition, we have leveraged our earlier stage capabilities to establish multiple partnerships and collaborations with leading pharmaceutical and biopharmaceutical companies. These partnerships are designed to advance the development of a variety of targeted therapies. We are committed to excellence in all aspects of our work and are dedicated to improving the care and outcome of cancer patients. About Us COMETRIQ® Pipeline Clinical Trials Medical Information Investors & Media Responsibility Careers About Us Management Board of Directors Collaborations Locations Contact Us © Exelixis, Inc. 2014 Website design: Hane Chow, Inc. Privacy Terms of Use